Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C-C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: Provided are antibodies and fragments having binding specificity to the signal regulatory protein alpha (SIRP?) protein and to the programmed death-ligand 1 (PD-L1) protein. The antibodies and fragments can bring peripheral macrophages to PD-L1+ tumor site, thereby enhancing tumor treatment.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C—C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the ?3-?4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the ?5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Abstract: Provided are chimeric antigen receptors that include an antibody or fragment thereof having binding specificity to the human GPRC5D protein. The chimeric antigen receptors and immune cells expressing the chimeric antigen receptors are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Abstract: Wire arc additive manufacturing-spinning combined machining device and method are provided. The machining device includes a spinning mechanism and a fused deposition modeling mechanism. The spinning mechanism includes a machine tool and a spinning head. The spinning head is installed on the machine tool by a main shaft, and the main shaft is configured to drive the spinning head to rotate to achieve the movement in three vertical directions. The spinning head includes a spinning base and balls. Each of the balls is installed in a corresponding one of arc grooves at a bottom of the spinning base. The fused deposition modeling mechanism includes a moving track, a robot and a heat source generator. The arc moving track is arranged around the machine tool in a surrounding mode. The robot is movably installed on the moving track. The heat source generator is installed at a tail end of the robot.

Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the ?3-?4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the ?5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human GPRC5D protein. The antibodies or fragment thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human GPRC5D protein. The antibodies or fragment thereof are capable of targeting cancer cells expressing GPRC5D, and thus can be used to treat the cancer, in particular hematological cancer.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the human chemokine (C-C motif) receptor 8 (CCR8) protein. These antibodies are capable of binding to CCR8 at high affinity and can mediate antibody-dependent cellular cytotoxicity (ADCC).

Abstract: Provided are antibodies or fragments thereof having binding specificity to both variant 1 and variant 2 of the signal regulatory protein alpha (SIRP?) protein. The antibodies and fragments can dose-dependently and efficiently block the interaction between SIRP? and CD47, and effectively induce macrophage-mediated phagocytosis of tumor cells expressing CD47.

Abstract: Provided are antibody-drug conjugates containing a drug moiety attached to an antibody or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein. The antibody or the fragment thereof binds to the ?3-?4 loop (residues 45-63 of SEQ ID NO: 30, NYQGLWRSCVRESSGFTEC) and the ?5 strand (residues 169-172 of SEQ ID NO: 30, YTFG) of CLDN18.2.

Abstract: A welding bead modeling method for wire-arc additive manufacturing, a device therefor and a system therefor including using a dynamic parameter method, and using different welding process parameters in the same welding bead in the a wire-arc additive manufacturing process to obtain a welding bead with synchronous and dynamic changes in profile along with the dynamic changes of the welding process parameters. The method further comprising using a line laser sensor for scanning to obtain the segmented profile of the processed welding bead, and corresponding each welding bead profile to the welding process parameters one by one to train the neural network as training data, so as to obtain a welding bead modeling model capable of obtaining the corresponding welding bead profile according to the input welding process parameters.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: A system and a method are disclosed for detecting and regulating a microstructure online with an electromagnetic assistance. The system comprises a substrate, and a forming device, a detecting device and a regulating device located above the substrate, the detecting device is connected with the regulating device comprising an electromagnetic shock regulating unit and an electromagnetic stirring regulating unit; a workpiece may be formed layer by layer on the substrate through the forming device, the detecting device performs a real-time detection for the microstructure in a formed area, and transmits a detection result to the regulating device, and according to the detection result, the electromagnetic shock regulating unit may perform the electromagnetic shock on a newly formed fused micro area, or the electromagnetic stirring regulating unit may perform the electromagnetic stirring on a molten pool to regulate the microstructure of the workpiece.

Abstract: Provided are antibodies or fragment thereof having binding specificity to the wild-type human claudin 18.2 (CLDN18.2) protein and also capable of binding the M149L mutant. By contrast, such antibodies and fragments do not or weakly bind to claudin 18.1 (CLDN18.1).

Abstract: The present invention provide a method for identifying different isoform using long reads of RNA sequencing. The method includes assigning sequence tracks to a given gene locus based on long-read mapping against a reference genome wherein existing isoforms are also included as a sequence track, excluding long-read mappings that show few overlaps with existing exon or are in antisense to the given gene locus, clustering the sequence tracks based on a distance score Score 1, merging the sequence tracks with a cut-off based on the distance scores Score 1 between the sequence tracks, merging the sequence tracks if the distance score Score 1 is lower than 5%, clustering the retained sequence tracks based on a mutual distance score Score 2, merging the sequence track with a shorter length in the summed exons and correcting the resulting sequence tracks for intron/exon junctions to result in different isoforms.